In order to promote pharmaceutical research and development, Semmelweis University (SE) and Pfizer Gyógyszerkereskedelmi Kft. have signed a cooperation agreement, the signatories announced in a statement to MTI. The cooperation established in the field of clinical research increases the research and development capacity of Semmelweis University and contributes to increasing the number of clinical drug trials, they wrote.
According to the announcement, thanks to Pfizer's international INSPIRE (Investigator Networks, Site Partnerships and Infrastructure for Research Excellence) clinical trial site qualification, Semmelweis University has become one of the world's top clinical trial research sites, so it can join even more innovative trial programs that can help patients recovery, the development of domestic professionals and health care.
In its announcement, Pfizer wrote that human clinical trials are taking place worldwide as the most important stage in the extremely long process of drug development research, but resources are mostly concentrated in countries where the clinical research system is advanced and of adequate quality. The number of reliable, high-quality research sites, where the necessary expertise is available, is also a decisive factor.
The announcement quotes Péter Vereckei, the managing director of Pfizer Gyógyszerkereskedelmi Kft., who said that Hungary is consistently among the top ten countries in terms of the number of initiated clinical research among the countries where Pfizer operates. Between 2014 and 2018, the company spent HUF 16.4 billion on clinical research in Hungary, and in 2019, they used the research services of domestic specialists and institutions worth HUF 1.239 billion in their research aimed at developing new therapeutic procedures and medicines.
You can read the entire article on the
